

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/12/31	2015/12/31
Balance Sheet		
Current assets		
Total cash and cash equivalents	309,771	305,619
Total Current investments in debt instrument without active market	455,399	859,867
Notes receivable due from related parties, net	0	71
Accounts receivable, net	23,328	18,570
Accounts receivable due from related parties, net	24,472	0
Other receivables, net	2,838	2,892
Total current tax assets	1,907	4,038
Total inventories	50,395	22,627
Total prepayments	19,989	21,576
Total other current assets	48,402	9,323
Total current assets	936,501	1,244,583
Non-current assets		
Non-current financial assets at cost, net	20,000	0
Total Non-current investments in debt instrument without active market	30,000	30,000
Total property, plant and equipment	315,000	199,876
Total intangible assets	2,342	580
Deferred tax assets	39,599	40,173
Total other non-current assets	45,906	3,174
Total non-current assets	452,847	273,803
Total assets	1,389,348	1,518,386
Current liabilities		
Total accounts payable	22,069	19,619
Total accounts payable to related parties	0	40
Total other payables	42,658	30,362
Other payables to related parties	6	0
Total other current liabilities	5,728	11,618
Total current liabilities	70,461	61,639
Non-current liabilities		
Total deferred tax liabilities	473	796
Total other non-current liabilities	2,271	1,737
Total non-current liabilities	2,744	2,533
Total liabilities	73,205	64,172
Share capital		
Ordinary share	1,120,005	1,115,990
Advance receipts for share capital	807	2,211
Total share capital	1,120,812	1,118,201
Capital surplus		
Total capital surplus, additional paid-in capital	621,104	614,631
Capital surplus, treasury share transactions	2,812	2,812
Capital surplus, employee share options	15,695	3,876
Total capital surplus	639,611	621,319
Retained earnings		
Total unappropriated retained earnings (accumulated deficit)	-356,669	-197,695
Total retained earnings	-356,669	-197,695
Other equity interest		
Total other equity, others	0	0
Total other equity interest	0	0
Treasury shares	-87,611	-87,611
Total equity	1,316,143	1,454,214
Total liabilities and equity	1,389,348	1,518,386
Number of share capital awaiting retirement	0	0
Equivalent issue shares of advance receipts for ordinary share	44,000	116,000
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/4th	2015/4th
Income Statement		
Total operating revenue	200,606	134,857
Total operating costs	160,359	97,508
Gross profit (loss) from operations	40,247	37,349
Gross profit (loss) from operations	40,247	37,349
Operating expenses		
Total selling expenses	9,722	3,664
Total administrative expenses	31,155	29,788
Total research and development expenses	217,775	144,966
Total operating expenses	258,652	178,418
Net operating income (loss)	-218,405	-141,069
Non-operating income and expenses		
Total other income	63,259	29,867
Other gains and losses, net	-2,989	930
Total non-operating income and expenses	60,270	30,797
Profit (loss) from continuing operations before tax	-158,135	-110,272
Total tax expense (income)	350	617
Profit (loss) from continuing operations	-158,485	-110,889
Profit (loss)	-158,485	-110,889
Other comprehensive income		
Components of other comprehensive income that will not be reclassified to profit or loss		
Gains (losses) on remeasurements of defined benefit plans	-588	1,360
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-99	231
Other comprehensive income, net	-489	1,129
Total comprehensive income	-158,974	-109,760
Basic earnings per share		
Total basic earnings per share	-1.45	-1.01

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/4th	2015/4th
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-158,135	-110,272
Profit (loss) before tax	-158,135	-110,272
Depreciation expense	41,375	34,209
Amortization expense	1,044	1,282
Provision (reversal of provision) for bad debt expense	4	0
Interest income	-8,075	-13,952
Share-based payments	14,686	478
Loss (gain) on disposal of property, plan and equipment	205	0
Impairment loss on non-financial assets	610	74
Total adjustments to reconcile profit (loss)	49,849	22,091
Decrease (increase) in notes receivable due from related parties	71	-71
Decrease (increase) in accounts receivable	-4,762	21,583
Decrease (increase) in accounts receivable due from related parties	-24,472	4,927
Decrease (increase) in other receivable	-231	5,213
Decrease (increase) in inventories	-28,378	-7,736
Decrease (increase) in prepayments	1,587	-9,009
Decrease (increase) in other current assets	-465	648
Total changes in operating assets	-56,650	15,555
Increase (decrease) in accounts payable	2,450	8,186
Increase (decrease) in accounts payable to related parties	-40	17
Increase (decrease) in other payable	7,977	4,478
Increase (decrease) in other payable to related parties	6	0
Increase (decrease) in other current liabilities	-5,890	-3,795
Increase (decrease) in net defined benefit liability	-54	131
Total changes in operating liabilities	4,449	9,017
Total changes in operating assets and liabilities	-52,201	24,572
Total adjustments	-2,352	46,663
Cash inflow (outflow) generated from operations	-160,487	-63,609
Income taxes refund (paid)	2,131	-1,310
Net cash flows from (used in) operating activities	-158,356	-64,919
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-250,517	-1,035,889
Proceeds from disposal of investments in debt instrument without active market	654,985	1,301,771
Acquisition of financial assets at cost	-20,000	0
Acquisition of property, plant and equipment	-107,471	-63,928
Increase in refundable deposits	0	-1,348
Decrease in refundable deposits	439	0
Acquisition of intangible assets	-2,522	0
Increase in other financial assets	-51,207	-9,069
Decrease in other financial assets	12,593	0
Increase in prepayments for business facilities	-88,369	-153
Interest received	8,360	13,910
Net cash flows from (used in) investing activities	156,291	205,294
Cash flows from (used in) financing activities		
Exercise of employee share options	6,217	14,001
Payments to acquire treasury shares	0	-87,611
Net cash flows from (used in) financing activities	6,217	-73,610
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	4,152	66,765
Cash and cash equivalents at beginning of period	305,619	238,854
Cash and cash equivalents at end of period	309,771	305,619
Cash and cash equivalents reported in the statement of financial position	309,771	305,619
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

